Patrick Forde, MBBCh, offers crucial perspectives on breakthroughs in Non-Small Cell Lung Cancer from ESMO 2023.
EP. 1: CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC
Patrick Forde, MBBCh, shares insights on perioperative immunotherapy in the CheckMate-77T study presented at ESMO 2023.
Watch
EP. 2: Evolving NSCLC Landscape: Comparing Recent Updates in Neoadjuvant and Perioperative Immunotherapy
An expert comparison of recent data on neoadjuvant and perioperative immunotherapy in resectable early-stage NSCLC, including CheckMate 77T, CheckMate-816, and KEYNOTE-671.
EP. 3: Updates in ALK+ NSCLC: ALINA Trial at ESMO 2023
Patrick Forde, MBBCh, discusses ALK rearrangement in NSCLC and highlights ALINA trial results from ESMO 2023.
EP. 4: Lessons from LIBRETTO-431 Trial in RET+ NSCLC
An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.
EP. 5: PAPILLON Trial Insights: ESMO 2023
Patrick Forde, MBBCh, discusses advances in EGFR Exon 20 insertion-mutated NSCLC.
EP. 6: Innovations Needed and Future Directions in Treatment of NSCLC
Concluding thoughts on data presented at ESMO 2023, and innovations still needed for improved survival of NSCLC—provided by Patrick Forde, MBBCh.
More Than 250 Million Individuals Unaware They Have Diabetes
Home-Based Couples Testing Best When Complemented With Counselling
Experts Address Health Care Gaps Exposed by COVID-19 Pandemic
Unique Challenges for Younger NHL Populations: Andrew Evens, DO